|Bid||31.00 x 100|
|Ask||35.00 x 100|
|Day's Range||32.34 - 32.74|
|52 Week Range||29.83 - 42.97|
|PE Ratio (TTM)||35.23|
|Forward Dividend & Yield||0.31 (0.97%)|
|1y Target Est||31.50|
After looking at Dr Reddy’s Laboratories Limited’s (NSEI:DRREDDY) latest earnings update (31 December 2017), I found it helpful to revisit the company’s performance in the past couple of years andRead More...
Dr. Reddy’s Laboratories Ltd and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application for its migraine candidate DFN-02 with the U.S.
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Dr Reddy’s Laboratories Limited (NSEI:DRREDDY), with a market cap of ₹348.85B, are often out ofRead More...
Celgene shares lifted Monday on the likelihood it's approaching a settlement with Dr. Reddy's over a generic version of blockbuster cancer drug Revlimid.
Dr. Reddy’s Laboratories Ltd. announced today that it has launched Palonosetron Hydrochloride Injection, 0.25 mg / 5 mL, a therapeutic equivalent generic version of ALOXI® Injection approved by the U.S.
Stock Monitor: Amphastar Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Dr. Reddy's Laboratories Ltd (NYSE: RDY ...
Dr. Reddy’s Laboratories Ltd announced today that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of Xyzal® Allergy 24HR Tablets in the United States market as approved by the U.S.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Dr Reddy’s Laboratories Limited (NSEI:DRREDDY) is currently trading at a trailing P/E of 36.5x, which is higher than the industry average of 29.5x. While this makes DRREDDY appear like aRead More...
Dr. Reddy’s Laboratories Ltd announced today that it has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine® in the United States market approved by the U.S.
Dr Reddy’s Laboratories Limited (NSEI:DRREDDY) delivered a less impressive 9.50% ROE over the past year, compared to the 13.67% return generated by its industry. Though DRREDDY’s recent performance is underwhelming,Read More...
Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
The Hyderabad, India-based company said it had profit of 32 cents per share. Earnings, adjusted for pretax expenses, were 41 cents per share. The pharmaceutical posted revenue of $596 million in the period. ...
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the third quarter and nine months ended December 31, 2017 under International Financial Reporting Standards .
Dr. Reddy's Laboratories will announce results for the Third Quarter ended December 31, 2017 on Thursday, January 25, 2018 after the Board Meeting.
Dr. Reddy’s Laboratories Ltd announced that the Company will be presenting at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Measuring Dr Reddy’s Laboratories Limited’s (NSEI:DRREDDY) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met orRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dr. Reddy’s Laboratories Ltd. Here are 5 ETFs with the largest exposure to RDY-US. Comparing the performance and risk of Dr. Reddy’s Laboratories Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Dr. Reddy’s Laboratories Ltd. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Dr. Reddy’s Laboratories Ltd. – Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Cipla Limited Sponsored GDR 144A and Wockhardt Limited Sponsored GDR (PFE-US, TEVA-US, CPLFY-US and ... Read more (Read more...)
Dr. Reddy’s Laboratories Ltd announced today that it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran® for Injection in the United States market approved by the U.S.
The latest earnings release Dr Reddy’s Laboratories Limited’s (NSEI:DRREDDY) announced in September 2017 suggested that the company experienced a significant headwind with earnings deteriorating by -39.84%. Today I want toRead More...
—The US subsidiary of Dr. Reddy’s Laboratories Ltd. announced today that it has reached a settlement with the US Government, in a case that is more than six years old, involving packaging for five blister-packed prescription products.
The settlement was disclosed in documents filed in federal court in Trenton, New Jersey, over a year after the U.S. Consumer Product Safety Commission voted to refer a case involving the drugmaker to the U.S. Justice Department. Dr. Reddy's in a statement said that the safety of patients and consumers was of "paramount importance" to the company. It said it disagreed with the allegations but agreed to the settlement to avoid prolonged litigation.